FDA warns Novo Nordisk over failures to report and investigate serious unexpected adverse drug experiences for drugs including semaglutide.
What happened
FDA inspected Novo Nordisk Inc. from January 13 to February 7, 2025, and reviewed postmarketing adverse drug experience reporting. FDA found written procedures and contractor practices that let serious and unexpected adverse events go unreported or delayed, including a liraglutide stroke case, a semaglutide death case, and a semaglutide suicidal ideation case.
What FDA found
Procedures allowed serious and unexpected adverse events to be rejected as unrelated, even though FDA requires reporting whether or not the event is considered drug-related.
21 CFR 314.80(b), 314.80(c)(1)(i)The company failed to submit serious and unexpected adverse drug experiences to FDA within 15 calendar days.
21 CFR 314.80(c)(1)(i)Call-center contractors invalidated 15-day reports for missing patient identifiers even when identifiers were present in source documents.
21 CFR 314.80(b), 314.80(c)(1)(i)Cases stayed in medical review beyond the company's own timelines, delaying required 15-day reports.
21 CFR 314.80(c)(1)(i)Procedures did not require follow-up on adverse events when the reporter was not a health care professional and consent was not obtained, so serious cases were not promptly investigated.
21 CFR 314.80(c)(1)(ii)
What FDA wants
Within 15 business days of receipt, notify FDA in writing of actions taken to prevent similar violations. FDA also asks for details on each major pharmacovigilance deviation after January 1, 2021, including root cause, impact, corrective and preventive action status, and effectiveness-check results.
Who should pay attention
- drug application holders with FDA postmarketing safety reporting duties
- companies that use contractors or call centers for adverse event intake
- patient safety and pharmacovigilance teams at drug manufacturers
This is a summary. Read the original letter on fda.gov.